• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brad Perriello

Bayer leads One Drop’s $40m Series B, inks deal to expand past diabetes

September 17, 2019 By Brad Perriello

Bayer gets in on One Drop

Bayer (ETR:BAYN) led a $40 million Series B round for glucose monitor maker One Drop, licensed its platform for treating conditions beyond diabetes and put its pharma president on the One Drop board. New York City-based One Drop developed a compact blood glucose monitor, pairing it with an app designed to provide behavioral cues and one-on-one coaching. […]

Filed Under: Diabetes, Featured, Funding Roundup, mHealth (Mobile Health) Tagged With: Bayer AG, One Drop

Dexcom claims win in patent war with AgaMatrix unit WaveForm

August 26, 2019 By Brad Perriello

Dexcom, AgaMatrix

Dexcom Inc. (NSDQ:DXCM) last week claimed a win along one front of its patent war with AgaMatrix subsidiary WaveForm Technologies, when an Oregon federal court dismissed a lawsuit alleging that its continuous glucose monitors infringe WaveForm patents. Wilsonville, Ore.-based WaveForm sued Dexcom in March 2016, alleging infringement of a trio of patents covering a compound […]

Filed Under: Diabetes, Featured, Legal News Tagged With: agamatrix, DexCom Inc., waveformtechnologies

Study: No difference between Biotronik, Medtronic or Boston Scientific stents

August 20, 2019 By Brad Perriello

coronary stent

A study comparing drug-eluting stents made by Biotronik, Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) found no statistically significant difference on target vessel failure or stent thrombosis after three years. The 3,514-patient Bio-Resort trial compared Biotronik’s Orsiro biodegradable sirolimus-eluting stent, Medtronic’s thin-strut zotarolimus-eluting Resolute Integrity stent and the Synergy biodegradable everolimus-eluting stent. Three-year results for some 3,393 […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents Tagged With: Biotronik, Boston Scientific, Medtronic

Veramorph lands spot in Delaware accelerator

July 30, 2019 By Brad Perriello

Veramorph Materials

Veramorph Materials landed a spot in a Delaware business accelerator backed by DuPont to develop its hydrogel-based oral drug delivery platform. Veramorph and MCET Technologies (which is developing wearable sensor technology) won their spots in the Delaware Innovation Space via the DuPont FastPass competition. The companies get a year of free access to the accelerator, […]

Filed Under: Featured, Funding Roundup, Hydrogels Tagged With: Veramorph Materials

Pfizer to absorb Mylan in off-patent drug spinout

July 29, 2019 By Brad Perriello

Pfizer to merge Upjohn with Mylan

Pfizer (NYSE:PFE) plans to absorb Mylan (NSDQ:MYL) as part of the spinout of its Upjohn off-patent drugs business in an all-stock deal. The deal, structured to avoid taxes on any gains from the spinout, would see each Mylan share converted into a share of the as-yet-unnamed new company. Pfizer stockholders would then own 57% of […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Mylan, Pfizer Inc.

FDA approves delivery system for Intersect ENT’s Propel implant

July 26, 2019 By Brad Perriello

Intersect ENT updated

Intersect ENT (NSDQ:XENT) said today that it won FDA approval for a new delivery system for its Propel Mini steroid-eluting sinus implant. The Menlo Park, Calif.-based company said the straight delivery system is designed to place the mometasone furoate-eluting Propel Mini in the ethmoid sinus behind the nasal bridge. The SDS is slated to hit […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Otolaryngology Ear, Nose & Throat, Regulatory/Compliance Tagged With: Intersect ENT Inc.

Livongo share prices double after upsized $356m IPO

July 25, 2019 By Brad Perriello

Livongo

Investors added nearly 50% to the share price for Livongo Health (NSDQ:LVGO) today after it raised $355 million with its initial public offering after a last-minute upsizing. The Mountain View, Calif.-based company, which developed a digital health platform to manage chronic diseases, said earlier this week that it planned to float 10.7 million shares at $24 […]

Filed Under: Diabetes, Featured, Funding Roundup, Initial Public Offering (IPO), mHealth (Mobile Health), Wall Street Beat Tagged With: livongohealth

Eli Lilly, Aptar win FDA approval for nasal glucagon powder

July 25, 2019 By Brad Perriello

FDA approves Baqsimi

Eli Lilly (NYSE:LLY) and AptarGroup (NYSE:ATR) today won FDA approval for the first injection-free glucagon for treating severe low blood sugar in diabetes patients. The federal safety watchdog’s approval, of Lilly’s Baqsimi nasal powder and the delivery device developed by Aptar for treating severe hypoglycemia, was based on two studies comparing a single dose of Baqsimi […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: aptarpharma, Eli Lilly & Co.

Livongo boosts IPO to $268m midpoint

July 23, 2019 By Brad Perriello

Livongo

Livongo Health yesterday boosted the range on its pending initial public offering, saying the flotation would now fetch nearly $268 million at the midpoint. The Mountain View, Calif.-based company developed a digital health platform to manage chronic diseases, selecting diabetes as its first target. After a series of upsizing announcements, Livongo yesterday said it plans […]

Filed Under: Diabetes, Featured, Funding Roundup, Wall Street Beat Tagged With: livongohealth

Medtronic bids for expanded FDA indication for Guardian Sensor 3

July 23, 2019 By Brad Perriello

Medtronic's Guardian Sensor 3

Medtronic (NYSE:MDT) said it asked the FDA for an expanded indication for its Guardian Sensor 3 device that would open the glucose sensor up for Medicare reimbursement. The Fridley, Minn.-based medtech titan said it filed for pre-market approval of non-adjunctive labeling for Guardian Sensor 3 for use with its MiniMed 670G insulin management system. If […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Medtronic

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 14
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS